NCT06894212: A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
- State
- Under way
- Phase
- Phase 3
- People
- 538 taking part
- Started
- 28 Feb 2025
- Primary completion
- 20 Oct 2026
- Arms
- SEP-363856 75 mg, SEP-363856 100 mg
- Results
- None posted
- 28 Feb 2025: Trial started
- 25 Mar 2025: Trial registered